A research note from Jarden has valued NZX-listed biotech Pacific Edge at double its current share price, citing the long-term commercial potential of its bladder cancer diagnostic technology, just need access to read full article - https://www.facebook.com/NBROnline/
- Forums
- ASX - By Stock
- PEB
- Analysts pick Pacific Edge to double in value
PEB
pacific edge limited
Add to My Watchlist
0.00%
!
10.5¢

Analysts pick Pacific Edge to double in value
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
The Watchlist
P.HOTC
HotCopper
Frazer Bourchier, Director, President and CEO
Frazer Bourchier
Director, President and CEO
SPONSORED BY The Market Online